-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical News, February 23.
Heavy documents flowed out, involving multiple points.
Recently, the industry has circulated a work point about medical insurance work in 2021, which involves many key content of the industry’s readers, including centralized procurement, medical insurance catalog and DRG Pilot
.
The "Work Points" clarified the normalized and institutionalized implementation of centralized bidding and procurement of pharmaceuticals and consumables , and the normalized and institutionalized centralized procurement of pharmaceuticals and consumables should be carried out
.
Promote the fourth and fifth batches of national-organized centralized drug procurement, and implement the results of the national-organized centralized procurement of coronary stents
.
Explore the establishment of an alliance procurement mechanism, expand the centralized procurement of medicines, and carry out centralized procurement of medical consumables in layers, classifications, and batches
.
Improve the provincial-level platform Sunshine Internet-linked procurement system, standardize the rules for network-linking and withdrawal, promote information linkage, and gradually realize that all public medical institutions purchase all the drugs and medical consumables they need from the provincial-level platform
.
In addition to the normalization of centralized procurement and the promotion of the fifth batch of national procurement news, the adjustment of the medical insurance catalog is another topic of concern to the pharmaceutical industry
.
The "Work Points" mentioned that the 2020 version of the medical insurance drug catalog will be implemented, and the monitoring of the negotiated drug landing will be organized
.
The dynamic adjustment of the 2021 drug catalog will be carried out
.
We will do a good job in the clean-up and digestion of the provincial supplemental drug list to ensure that the drug list will be basically unified nationwide by 2022
.
In addition, the management measures for medical insurance consumables were promulgated, and the non-category national medical insurance consumables access catalogue was explored
.
Formulate medical insurance drug payment standards, and gradually promote the integration of medical insurance catalog management and medical insurance payment standards
.
Research and improve medical insurance payment policies for medical service items
.
Research and improve the protection mechanism of drugs for special rare diseases
.
Improve the total budget management, actively promote the regional point-based total budget and the trial of payment by disease points (DIP), continue to do a good job in the national trial of payment by disease diagnosis-related group (DRG), and the pilot cities will enter the actual payment by the end of 2021
.
Research and improve medical insurance payment methods adapted to outpatient medical services, and rely on primary medical institutions to explore per capita payment methods for chronic diseases such as hypertension and diabetes
.
We will study the policy of close county medical community total payment, strengthen supervision and assessment, and improve the incentive mechanism
.
Implement the "Interim Measures for the Management of Medical Security in Medical Institutions" and "Interim Measures for the Management of Medical Security in Retail Pharmacies " to improve the management of medical insurance agreements
.
Promoting the fifth batch of national
procurement On February 8, after a four-day publicity period, Shanghai Sunshine Pharmaceutical Purchasing Network announced the official selection results of the fourth batch of national procurement, which means that the fourth batch of national procurement that affects the industry has come to an end.
It is expected that patients across the country will be In May, the medicines after the price reduction of the centralized procurement were used
.
In this centralized procurement, a total of 45 varieties and 80 product regulations were included, and the maximum purchase scale was over 25 billion yuan.
It is estimated that 12.
4 billion yuan will be saved in drug costs each year
.
There are 158 products to be selected, compared with the highest effective declared price, the average price of the drugs to be selected is reduced by 52%, with the highest drop of 96% (Qilu Pharmaceutical's Parecoxib Sodium for Injection)
.
The scope of centralized procurement covers diabetes, hypertension, respiratory diseases, psychotherapy, tumor medication, fungal infection, anesthesia pain, eye drops, etc.
, including 7 national medical insurance Class A drugs, 35 Class B drugs, and 2 non-medical insurances.
Products (ibuprofen injection and bivalrudine for injection)
.
In the official news previously announced, the National Medical Insurance Administration has made it clear that eligible drugs have reached a certain quantity or amount, that is, it will start centralized procurement with a certain amount.
To start a batch of centralized procurement, a certain amount of quantity must be accumulated, which is referred to as “basket” for short.
Will recruit one by one, the selection conditions are focused on the medical insurance catalog, clinically necessary, large amount of medication, and high amount of money, thus forming a trigger mechanism for centralized procurement
.
This time, it is clearly stated in the "Work Points" that the promotion of the fifth batch of centralized procurement in 2021 indicates to a certain extent that the conditions for the fifth batch of varieties that meet the rules have matured
.
The fourth batch of centralized procurement varieties has been successfully expanded to clinical large varieties of injections-involving a total of 8 injection varieties.
In 2019, the income of sample hospitals accounted for more than 30% of the total income of 45 varieties of sample hospitals
.
Whether there are further innovations in the selection of varieties in the fifth batch of centralized procurement, such as the inclusion of biological products and proprietary Chinese medicines, will become the focus of the industry in the future
.
From the perspective of time, according to the discussion of Fengyun medicine, starting from the second batch, the approximate time for each batch to be purchased has been relatively clear
.
The second batch of schedule:
Daily amount: 2019.
11.
28
Statistics: 2019.
12.
10 --12 days to complete statistical
release: 2020.
01.
13 --44 days newspaper published price and the amount
Quote: 2020.
01.
17--47 days to complete the public offer -Preparation time of four days after release
.
Spring Festival: 2020.
01.
25 ——Complete the third batch of timetables 8 days
before the Spring Festival: Volume: 2020.
06.
22 Statistics: 2020.
07.
09 ——Complete statistics in 17 days Release: 2020.
07.
29 ——Release price limit and volume in 37 days Quotation: 2020.
08.
20
- 59 days to complete the offer publicity
fourth installment schedule:
Daily amount: 2020.
12.
10
Statistics: 2021.
01.
01 --21 days to complete statistical
release: January 15 - Post reported that the amount of 18 days to complete the quote
quote: 2 Yue On the 3rd , quotation
Spring Festival: 2021.
02.
11 ——Completed 8 days before the Spring Festival.
Now, according to the timetable, perhaps in June this year, the fifth batch of mass purchases will arrive as scheduled
.
The latest progress of the medical insurance catalogue is
clearly defined in the "Key Points of Work", to implement the 2020 medical insurance drug catalogue, and to organize the implementation of the negotiated drug landing monitoring work
.
The dynamic adjustment of the 2021 drug catalog will be carried out
.
We will do a good job in the clean-up and digestion of the provincial supplemental drug list to ensure that the drug list will be basically unified nationwide by 2022
.
This originated on August 20, 2019, when the National Medical Insurance Administration issued the "Notice of the Ministry of Human Resources and Social Security of the National Medical Insurance Administration on Printing and Distributing the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Lists"
.
The "Notice" clarified that all localities should strictly implement the "Drug List", and they must not formulate their own lists or use alternative methods to add drugs in the list, and they must not adjust the limited payment scope for drugs in the list by themselves
.
For Class B drugs that were added as required in the original provincial drug catalog, they should be gradually digested within 3 years
.
During the digestion process, each province should give priority to adjusting the drugs included in the national key monitoring scope out of the payment scope
.
The arrangements for the transfer of local supplements to the medical insurance are as follows: 1.
The drugs under the key monitoring catalogue are first removed from the medical insurance catalog; 2.
The remaining local supplements will be cleared within three years in principle, and the proportions of the three-year cleared varieties are 40%, 40%, and 20 respectively.
%
.
Cyberlane sorted out the retrieving documents of the supplementary varieties of various provinces and found that more than 20 provinces, including Gansu, Ningxia, Xinjiang, Guangxi, Zhejiang, and Shaanxi, have implemented local supplementary catalog retrieving policies; among them, Yunnan and Hunan , Jilin, Tianjin, Hebei, Anhui, Tibet and other places have clarified the first batch of supplementary varieties to be transferred from local medical insurance, and these varieties have been transferred from the local medical insurance catalogue on July 1, 2020
.
In addition, Beijing, Ningxia, Xinjiang, Guangxi, Chongqing and other places also announced the final adjustment and digestion time
.
On the whole, the deadline for the withdrawal of local supplementary products from medical insurance is mainly concentrated at the end of June 2022, which meets the final time limit requirements of the "Work Essentials"
.
Heavy documents flowed out, involving multiple points.
Recently, the industry has circulated a work point about medical insurance work in 2021, which involves many key content of the industry’s readers, including centralized procurement, medical insurance catalog and DRG Pilot
.
The "Work Points" clarified the normalized and institutionalized implementation of centralized bidding and procurement of pharmaceuticals and consumables , and the normalized and institutionalized centralized procurement of pharmaceuticals and consumables should be carried out
.
Promote the fourth and fifth batches of national-organized centralized drug procurement, and implement the results of the national-organized centralized procurement of coronary stents
.
Explore the establishment of an alliance procurement mechanism, expand the centralized procurement of medicines, and carry out centralized procurement of medical consumables in layers, classifications, and batches
.
Improve the provincial-level platform Sunshine Internet-linked procurement system, standardize the rules for network-linking and withdrawal, promote information linkage, and gradually realize that all public medical institutions purchase all the drugs and medical consumables they need from the provincial-level platform
.
In addition to the normalization of centralized procurement and the promotion of the fifth batch of national procurement news, the adjustment of the medical insurance catalog is another topic of concern to the pharmaceutical industry
.
The "Work Points" mentioned that the 2020 version of the medical insurance drug catalog will be implemented, and the monitoring of the negotiated drug landing will be organized
.
The dynamic adjustment of the 2021 drug catalog will be carried out
.
We will do a good job in the clean-up and digestion of the provincial supplemental drug list to ensure that the drug list will be basically unified nationwide by 2022
.
In addition, the management measures for medical insurance consumables were promulgated, and the non-category national medical insurance consumables access catalogue was explored
.
Formulate medical insurance drug payment standards, and gradually promote the integration of medical insurance catalog management and medical insurance payment standards
.
Research and improve medical insurance payment policies for medical service items
.
Research and improve the protection mechanism of drugs for special rare diseases
.
Improve the total budget management, actively promote the regional point-based total budget and the trial of payment by disease points (DIP), continue to do a good job in the national trial of payment by disease diagnosis-related group (DRG), and the pilot cities will enter the actual payment by the end of 2021
.
Research and improve medical insurance payment methods adapted to outpatient medical services, and rely on primary medical institutions to explore per capita payment methods for chronic diseases such as hypertension and diabetes
.
We will study the policy of close county medical community total payment, strengthen supervision and assessment, and improve the incentive mechanism
.
Implement the "Interim Measures for the Management of Medical Security in Medical Institutions" and "Interim Measures for the Management of Medical Security in Retail Pharmacies " to improve the management of medical insurance agreements
.
Promoting the fifth batch of national
procurement On February 8, after a four-day publicity period, Shanghai Sunshine Pharmaceutical Purchasing Network announced the official selection results of the fourth batch of national procurement, which means that the fourth batch of national procurement that affects the industry has come to an end.
It is expected that patients across the country will be In May, the medicines after the price reduction of the centralized procurement were used
.
In this centralized procurement, a total of 45 varieties and 80 product regulations were included, and the maximum purchase scale was over 25 billion yuan.
It is estimated that 12.
4 billion yuan will be saved in drug costs each year
.
There are 158 products to be selected, compared with the highest effective declared price, the average price of the drugs to be selected is reduced by 52%, with the highest drop of 96% (Qilu Pharmaceutical's Parecoxib Sodium for Injection)
.
The scope of centralized procurement covers diabetes, hypertension, respiratory diseases, psychotherapy, tumor medication, fungal infection, anesthesia pain, eye drops, etc.
, including 7 national medical insurance Class A drugs, 35 Class B drugs, and 2 non-medical insurances.
Products (ibuprofen injection and bivalrudine for injection)
.
In the official news previously announced, the National Medical Insurance Administration has made it clear that eligible drugs have reached a certain quantity or amount, that is, it will start centralized procurement with a certain amount.
To start a batch of centralized procurement, a certain amount of quantity must be accumulated, which is referred to as “basket” for short.
Will recruit one by one, the selection conditions are focused on the medical insurance catalog, clinically necessary, large amount of medication, and high amount of money, thus forming a trigger mechanism for centralized procurement
.
This time, it is clearly stated in the "Work Points" that the promotion of the fifth batch of centralized procurement in 2021 indicates to a certain extent that the conditions for the fifth batch of varieties that meet the rules have matured
.
The fourth batch of centralized procurement varieties has been successfully expanded to clinical large varieties of injections-involving a total of 8 injection varieties.
In 2019, the income of sample hospitals accounted for more than 30% of the total income of 45 varieties of sample hospitals
.
Whether there are further innovations in the selection of varieties in the fifth batch of centralized procurement, such as the inclusion of biological products and proprietary Chinese medicines, will become the focus of the industry in the future
.
From the perspective of time, according to the discussion of Fengyun medicine, starting from the second batch, the approximate time for each batch to be purchased has been relatively clear
.
The second batch of schedule:
Daily amount: 2019.
11.
28
Statistics: 2019.
12.
10 --12 days to complete statistical
release: 2020.
01.
13 --44 days newspaper published price and the amount
Quote: 2020.
01.
17--47 days to complete the public offer -Preparation time of four days after release
.
Spring Festival: 2020.
01.
25 ——Complete the third batch of timetables 8 days
before the Spring Festival: Volume: 2020.
06.
22 Statistics: 2020.
07.
09 ——Complete statistics in 17 days Release: 2020.
07.
29 ——Release price limit and volume in 37 days Quotation: 2020.
08.
20
- 59 days to complete the offer publicity
fourth installment schedule:
Daily amount: 2020.
12.
10
Statistics: 2021.
01.
01 --21 days to complete statistical
release: January 15 - Post reported that the amount of 18 days to complete the quote
quote: 2 Yue On the 3rd , quotation
Spring Festival: 2021.
02.
11 ——Completed 8 days before the Spring Festival.
Now, according to the timetable, perhaps in June this year, the fifth batch of mass purchases will arrive as scheduled
.
The latest progress of the medical insurance catalogue is
clearly defined in the "Key Points of Work", to implement the 2020 medical insurance drug catalogue, and to organize the implementation of the negotiated drug landing monitoring work
.
The dynamic adjustment of the 2021 drug catalog will be carried out
.
We will do a good job in the clean-up and digestion of the provincial supplemental drug list to ensure that the drug list will be basically unified nationwide by 2022
.
This originated on August 20, 2019, when the National Medical Insurance Administration issued the "Notice of the Ministry of Human Resources and Social Security of the National Medical Insurance Administration on Printing and Distributing the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Lists"
.
The "Notice" clarified that all localities should strictly implement the "Drug List", and they must not formulate their own lists or use alternative methods to add drugs in the list, and they must not adjust the limited payment scope for drugs in the list by themselves
.
For Class B drugs that were added as required in the original provincial drug catalog, they should be gradually digested within 3 years
.
During the digestion process, each province should give priority to adjusting the drugs included in the national key monitoring scope out of the payment scope
.
The arrangements for the transfer of local supplements to the medical insurance are as follows: 1.
The drugs under the key monitoring catalogue are first removed from the medical insurance catalog; 2.
The remaining local supplements will be cleared within three years in principle, and the proportions of the three-year cleared varieties are 40%, 40%, and 20 respectively.
%
.
Cyberlane sorted out the retrieving documents of the supplementary varieties of various provinces and found that more than 20 provinces, including Gansu, Ningxia, Xinjiang, Guangxi, Zhejiang, and Shaanxi, have implemented local supplementary catalog retrieving policies; among them, Yunnan and Hunan , Jilin, Tianjin, Hebei, Anhui, Tibet and other places have clarified the first batch of supplementary varieties to be transferred from local medical insurance, and these varieties have been transferred from the local medical insurance catalogue on July 1, 2020
.
In addition, Beijing, Ningxia, Xinjiang, Guangxi, Chongqing and other places also announced the final adjustment and digestion time
.
On the whole, the deadline for the withdrawal of local supplementary products from medical insurance is mainly concentrated at the end of June 2022, which meets the final time limit requirements of the "Work Essentials"
.
